Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,892 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04094688 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer(SOLARIS) | active not recruiting | Phase 3 | 455 | Alliance for Clinical Trials in OncologyOTHER | 2 | Mar 3, 2026 | clinicaltrials |
| NCT04215731 | Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer(FOBEAR) | recruiting | Phase 3 | 582 | Yanhong DengOTHER | 1 |
| Mar 3, 2026 |
| clinicaltrials |
| NCT04928807 | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) | active not recruiting | Phase 3 | 231 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04428905 | Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | active not recruiting | Phase 3 | 403 | City of Hope Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05171660 | Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 446 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT01460589 | Early Commencement of Adjuvant Chemotherapy for Colon Cancer(ECTX) | active not recruiting | Phase 3 | 303 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03426904 | Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer | active not recruiting | Phase 3 | 708 | Kyungpook National University HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06107920 | Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy(COnCERTO) | recruiting | Phase 3 | 232 | University Hospital, RouenOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07389265 | Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer(CAPRI-3 GOIM) | recruiting | Phase 3 | 480 | University of Campania Luigi VanvitelliOTHER | 2 | Feb 5, 2026 | clinicaltrials |
| NCT07384377 | JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan | not yet recruiting | Phase 3 | 123 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Feb 3, 2026 | clinicaltrials |
| NCT02448173 | A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer | not yet recruiting | Phase 3 | 550 | Vaccinogen IncINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04495088 | Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer | recruiting | Phase 3 | 550 | Ralf HofheinzOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04854668 | A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 748 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05843877 | Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula(XandTX) | recruiting | Phase 3 | 32 | Technische Universität DresdenOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07372300 | Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer(mEHT) | recruiting | Phase 3 | 126 | Shih-Kai HungOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04137107 | Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 220 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jan 26, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT07362836 | Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS) | not yet recruiting | Phase 3 | 224 | Fudan UniversityOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07361003 | A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer | recruiting | Phase 3 | 464 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03875781 | Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer(NORAD01) | recruiting | Phase 3 | 540 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 375 | Beijing Friendship HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04095299 | Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients(WW3) | recruiting | Phase 3 | 162 | Vejle HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07321847 | Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases(INJECTABL-3) | not yet recruiting | Phase 2 / Phase 3 | 717 | Immunophotonics, Inc.INDUSTRY | 0 | Jan 7, 2026 | clinicaltrials |
| NCT07309289 | NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer | recruiting | Phase 3 | 144 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06791512 | mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC(BASKETⅢ) | recruiting | Phase 3 | 166 | Jun HuangOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03869892 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.(SOLSTICE) | active not recruiting | Phase 3 | 856 | Institut de Recherches Internationales ServierOTHER | 25 | Dec 22, 2025 | clinicaltrials |
| NCT05902533 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation(REDEL) | active not recruiting | Phase 2 / Phase 3 | 33 | University of CincinnatiOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06686576 | A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 363 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05008809 | Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) | recruiting | Phase 3 | 507 | Dominik Paul ModestOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT07272772 | Colon Cancer Diagnosis With FAPI-PET Imaging | recruiting | Phase 2 / Phase 3 | 100 | Turku University HospitalOTHER_GOV | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06733038 | FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.(AtezoTRIBE2) | recruiting | Phase 3 | 238 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03829462 | Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients(NEXT-REGIRI) | active not recruiting | Phase 3 | 377 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06940947 | Endoscopic Therapy Or Surgery for Early Colon Cancer(ETHOS) | recruiting | Phase 3 | 434 | Norwegian Department of Health and Social AffairsOTHER_GOV | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05945901 | A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 669 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02505750 | Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma(OPERA) | active not recruiting | Phase 3 | 148 | Centre Antoine LacassagneOTHER | 3 | Sep 29, 2025 | clinicaltrials |
| NCT07155525 | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas(NBCA-MS) | recruiting | Phase 3 | 194 | Minia UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06207981 | Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA(KANALRAD) | recruiting | Phase 3 | 310 | Federation Francophone de Cancerologie DigestiveOTHER | 2 | Sep 2, 2025 | clinicaltrials |
| NCT06490536 | The Sagittarius Trial | recruiting | Phase 3 | 700 | IFOM ETS - The AIRC Institute of Molecular OncologyOTHER | 3 | Aug 29, 2025 | clinicaltrials |
| NCT07134205 | The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer | not yet recruiting | Phase 3 | 252 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Aug 21, 2025 | clinicaltrials |
| NCT07134218 | Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Changhai HospitalOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT07132008 | Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer | not yet recruiting | Phase 3 | 94 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT06958419 | Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC) | recruiting | Phase 2 / Phase 3 | 286 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases(ASAC) | active not recruiting | Phase 2 / Phase 3 | 466 | Oslo University HospitalOTHER | 3 | Jul 31, 2025 | clinicaltrials |
| NCT06866574 | A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males | active not recruiting | Phase 3 | 9,300 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06441565 | Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06839092 | Prophylactic PIPAC in Patients With High-risk Colorectal Cancer(PROPAC) | not yet recruiting | Phase 3 | 160 | Jeremy MeyerOTHER | 0 | Jul 30, 2025 | clinicaltrials |
| NCT07074353 | Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer(CinClare-2) | not yet recruiting | Phase 3 | 360 | Zhejiang Cancer HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 3, 2026source: clinicaltrials